What changed
Net sales from continuing operations were $550M, up 32.1% YoY, driven by Acthar Gel net sales of $227M (+25%) and XIAFLEX net sales of $164M on higher Peyronie's disease demand and net price. The company posted a net loss of $96M, narrowing from a $242M loss in the prior-year period on strong brand performance and merger synergies, though results included a $151M pre-tax loss on the Percocet divestiture. Keenova raised FY2026 pro forma net sales guidance to $2.00B-$2.025B and pro forma Adjusted EBITDA to $750M-$770M.
Why it matters
Net sales from continuing operations were $550M, up 32.1% YoY, driven by Acthar Gel net sales of $227M (+25%) and XIAFLEX net sales of $164M on higher Peyronie's disease demand and net price. The comp